The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
The fresh capital will propel Cordance into its first-in-human clinical trial
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Subscribe To Our Newsletter & Stay Updated
